tt2006

Cover Article: Basomedial Hypothalamic Injections of Neuropeptide Y Conjugated to Saporin Selectively Disrupt Hypothalamic Controls of Food Intake

This article is a summary of data presented in reference #1. Figures 1-4 are taken from that article. This work was funded by NS045520 and DK40498 to S. Ritter. Neuropeptide Y (NPY) conjugated to saporin (SAP), a ribosomal toxin, is a compound designed to selectively target and lesion NPY receptor-expressing cells. We conducted competitive binding

Cover Article: Basomedial Hypothalamic Injections of Neuropeptide Y Conjugated to Saporin Selectively Disrupt Hypothalamic Controls of Food Intake Read More »

Cover Article: Safety and Efficacy of Substance P-SAP

contributed by Jeffrey W. Allen, Ph.D.The author is currently a Senior Scientist in Emerging Therapies at Medtronic Neurological located in Minneapolis, MN.There is no association, financial or otherwise, between Medtronic, Inc. and Advanced Targeting Systems. Substance P-saporin (SP-SAP, Cat. #IT-07) is a targeted neurotoxin that selectively lesions cells containing the Neurokinin-1 (NK-1) receptor. Previous studies

Cover Article: Safety and Efficacy of Substance P-SAP Read More »

Targeting Tools: Fluorescent Conjugates

Antibodies conjugated to fluorescent dyes are vibrant and vital tools at a scientist’s disposal. ATS currently has six fluorescent conjugates in our catalog: Cy3-labeled 192-IgG (Cat. #AB-N43FL3), FITC-labeled Anti-Saporin (Cat. #AB-15APFL), Alexa 488-labeled 192-IgG (Cat. #AB-N43FLA), FITC-labeled Goat anti-rabbit IgG (Cat. #FL-04), Cy3- labeled anti-NGFr (Cat. #AB-N01APFL3), and Cy5-labeled anti- NGFr (Cat. #AB-N01APFL5). ATS also

Targeting Tools: Fluorescent Conjugates Read More »

Chronic Pain Drug – Update on SP-SAP Development

ATS continues to make progress toward human clinical trials with SP-SAP. Thanks to the financial support of the National Institutes of Health, National Institute of Mental Health, preclinical studies have been completed, protocols for drug production have been written and the first of two toxicology studies is done. This first study is a GLP toxicology

Chronic Pain Drug – Update on SP-SAP Development Read More »

Cover Article: Targeted Toxins in Pain

Summary of contribution to “Recontres en toxinologie, 2005”by Ronald G. Wiley, Neurology Service (127) – VA TVHS, 1310 24th Avenue, South, Nashville, TN 37212 The use of targeted toxins in neuroscience research has evolved over the past twenty-plus years from original suicide transport lesions using ricin to highly selective neuron type-specific lesions made with immunotoxins,

Cover Article: Targeted Toxins in Pain Read More »

Cover Article: The Biologically Active Cholecystokinin (26-33) peptide, [Tyr2-SO3]CCK-8, Retains High Affinity for CCK2 Receptors after Covalent Conjugation to Saporin

Contributed by Josephine Lai, Wenjun Zhang, Hamid Badghisi, Victor J. Hruby(1) and Frank Porreca, Departments of Pharmacology and Chemistry(1), The University of Arizona, Tucson, AZ 85724. Cholecystokinin (CCK) is widely distributed in the central nervous system and the gastrointestinal tract. The 33-amino acid peptide contains a carboxyl terminal octapeptide sequence Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2 which confers the biological activity

Cover Article: The Biologically Active Cholecystokinin (26-33) peptide, [Tyr2-SO3]CCK-8, Retains High Affinity for CCK2 Receptors after Covalent Conjugation to Saporin Read More »

Shopping Cart
Scroll to Top